Intec Pharma (NASDAQ:NTEC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Saturday. The brokerage currently has a $7.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price points to a potential upside of 9.93% from the company’s previous close.

According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “

Other equities analysts have also issued research reports about the company. Oppenheimer increased their price target on Intec Pharma from $10.00 to $15.00 and gave the company an “outperform” rating in a research report on Thursday, September 21st. Maxim Group set a $8.00 price target on Intec Pharma and gave the company a “buy” rating in a research report on Friday, November 17th. CIBC reiterated an “outperform” rating and issued a $15.00 price target (up previously from $10.00) on shares of Intec Pharma in a research report on Thursday, September 21st. Finally, ValuEngine lowered Intec Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $11.15.

Intec Pharma (NASDAQ NTEC) opened at $7.05 on Friday. Intec Pharma has a fifty-two week low of $4.20 and a fifty-two week high of $9.80.

Large investors have recently added to or reduced their stakes in the stock. Sectoral Asset Management Inc acquired a new position in shares of Intec Pharma in the 3rd quarter valued at $3,177,000. Caxton Corp acquired a new position in shares of Intec Pharma in the 3rd quarter valued at $681,000. Pura Vida Investments LLC acquired a new position in shares of Intec Pharma in the 3rd quarter valued at $895,000. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Intec Pharma by 5.0% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 522,200 shares of the biotechnology company’s stock valued at $2,977,000 after purchasing an additional 25,000 shares during the period. Institutional investors and hedge funds own 40.16% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/06/intec-pharma-ntec-rating-increased-to-buy-at-zacks-investment-research.html.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.